The educational session was centred around the HOPE study which provided evidence that patients with coexisting diabetes and hypertension or other cardiovascular risk factors should be treated with an ACE inhibitor at a therapeutic dose (specifically ramipril 10 mg) [9] to reduce cardiovascular morbidity and mortality. Here, ACE is linked to diabetes mellitus.